Start-up funding

Digital Insurance asks funders what we can expect as the world and industry emerge from the coronavirus era.

Total rounds experienced a holiday lull, but rounds over $10 million ticked higher.

The coronavirus pandemic did little to stop the trajectory of insurtech.

CEO Mario Schlosser said in a statement Monday that it had submitted its draft registration for an IPO to the SEC.

Buoy Health, a startup that makes a widely used Covid-19 symptom checker, has raised $37 million from investors including the venture arms of major insurers Cigna Holding Co., Humana Inc. and UnitedHealth Group.

About $5 billion has been invested in insurtech this year, and top-tier insurers have taken part in more than 60 deals.

The Columbus, Ohio-based company sold 24.2 million shares, together with investors selling 2.6 million shares of their own, at $27 each.

Bank will partner with Anthemis, which is one of the most active insurtech investors.

The startups will work closely with 18 member corporations to establish proofs of concept and partnerships.

The 23 rounds of more than $10 million is indicative of a noted shift toward mature companies.

As carriers, distributors, service providers and insurtechs consider how to adapt these initial pandemic responses into long-term strategies, we see heightened interest from investors to provide strategic support.

Despite a big dip in March and April, insurtech funding in the first half of 2020 is only 2% behind last year.

PasarPolis offers microinsurance, allowing ride-hailing drivers, couriers and online shoppers and sellers to buy protection that cost as little as a few U.S. cents.

Bias in underwriting also tackled in discussion at Insurtech NY.

Atlas Financial reported that it had filed a Letter of Intent for the insurtech to acquire two of its units.

Investment in a range of insurtechs, and a new collaboration for hurricane season from Aon.

Deal volume was down as bigger sums flowed to established players.

Self-service inspections for QBE, new owner for Majesco, health insurtech exits stealth.

The large raises of insurtechs that closed out the 2010s aren’t likely to issue in a new decade of pure-play dominance or signal the demise of legacy insurers.

The focus of investment is going to transition in a way that reflects a new phase of development for the insurtech space.